DexCom (NASDAQ:DXCM) Now Covered by Evercore ISI

Evercore ISI started coverage on shares of DexCom (NASDAQ:DXCM) in a research report sent to investors on Tuesday morning, Marketbeat reports. The brokerage issued an in-line rating and a $68.00 price objective on the medical device company’s stock.

Other equities research analysts have also recently issued reports about the company. Argus dropped their price objective on DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Sanford C. Bernstein restated an “outperform” rating and set a $84.00 target price on shares of DexCom in a research note on Monday, November 3rd. BTIG Research dropped their price target on shares of DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Robert W. Baird set a $82.00 price target on shares of DexCom in a research note on Friday, October 31st. Finally, Royal Bank Of Canada decreased their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $86.73.

DexCom Price Performance

Shares of DXCM opened at $61.69 on Tuesday. DexCom has a twelve month low of $54.11 and a twelve month high of $93.25. The company has a market capitalization of $24.06 billion, a P/E ratio of 42.84, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The firm has a 50 day moving average of $64.93 and a 200 day moving average of $76.23. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach purchased 18,200 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were acquired at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares in the company, valued at $8,417,840. This represents a 1.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 9,999 shares of company stock worth $619,391. 0.32% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Several institutional investors and hedge funds have recently bought and sold shares of DXCM. Greenfield Seitz Capital Management LLC increased its position in DexCom by 5.6% in the third quarter. Greenfield Seitz Capital Management LLC now owns 64,181 shares of the medical device company’s stock worth $4,319,000 after buying an additional 3,387 shares in the last quarter. CIBC Private Wealth Group LLC grew its stake in shares of DexCom by 374.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock valued at $195,666,000 after acquiring an additional 2,294,709 shares during the period. Watts Gwilliam & Co. LLC grew its stake in shares of DexCom by 0.5% during the 3rd quarter. Watts Gwilliam & Co. LLC now owns 36,746 shares of the medical device company’s stock valued at $2,473,000 after acquiring an additional 200 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in DexCom in the 3rd quarter worth approximately $4,607,000. Finally, Danske Bank A S bought a new stake in DexCom during the 3rd quarter worth approximately $20,304,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.